Back to School: How biopharma can reboot drug development. Access exclusive analysis here

The importance of being IgE

An FDA approval of Xolair omalizumab to treat moderate-to-severe allergic asthma, as recommended by an advisory panel last week, would draw more attention to the value of its molecular target, immunoglobulin E (IgE), in other indications. Now that litigation and arbitration has concluded between Xolair partners Tanox Inc., Genentech Inc. and Novartis AG, the three are considering their next steps for developing antibodies against IgE.

Evidence suggests that IgE could be an effective target for treating seasonal allergic rhinitis and food allergy. And while it may not have utility in

Read the full 909 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE